Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

For payers, claims for rare disease treatments used to be uncommon. Not now with an increasing number of new, high-priced ...

Alnylam Pharmaceuticals’ RNAi therapeutic vutrisiran has been recommended by the European Medicines Agency’s human medicines ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, ...

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained ...

The approvals of Onpattro, Givlaari, Oxlumo, and Leqvio combined with several partnerships have bolstered Alnylam's cash balance, and the company concluded fiscal 2024 with $2.69 billion in cash, cash ...

Discover Alnylam Pharmaceuticals' robust Q1 2025 earnings, highlighted by a 28% revenue growth and the successful launch of AMVUTTRA for ...

In its 10-Q report, Alnylam Pharmaceuticals stated that as of March 31, 2025, it had an accumulated deficit of $7.35 billion ...

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a ...

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago. These ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based company said ...